دورية أكاديمية
أعرض في EDS

Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial.

التفاصيل البيبلوغرافية
العنوان: Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial.
المؤلفون: Sposito AC; Division of Cardiology, State University of Campinas (Unicamp), Campinas, Sao Paulo, 13084-971, Brazil. sposito@unicamp.com.; Brazilian Heart Study Group, State University of Campinas (Unicamp), Campinas, Sao Paulo, 13084-971, Brazil. sposito@unicamp.com., Breder I; Division of Cardiology, State University of Campinas (Unicamp), Campinas, Sao Paulo, 13084-971, Brazil., Barreto J; Division of Cardiology, State University of Campinas (Unicamp), Campinas, Sao Paulo, 13084-971, Brazil., Breder J; Division of Cardiology, State University of Campinas (Unicamp), Campinas, Sao Paulo, 13084-971, Brazil., Bonilha I; Division of Cardiology, State University of Campinas (Unicamp), Campinas, Sao Paulo, 13084-971, Brazil., Lima M; Division of Cardiology, State University of Campinas (Unicamp), Campinas, Sao Paulo, 13084-971, Brazil., Oliveira A; Division of Cardiology, State University of Campinas (Unicamp), Campinas, Sao Paulo, 13084-971, Brazil., Wolf V; Division of Cardiology, State University of Campinas (Unicamp), Campinas, Sao Paulo, 13084-971, Brazil., Luchiari B; Division of Cardiology, State University of Campinas (Unicamp), Campinas, Sao Paulo, 13084-971, Brazil., do Carmo HR; Division of Cardiology, State University of Campinas (Unicamp), Campinas, Sao Paulo, 13084-971, Brazil., Munhoz D; Division of Cardiology, State University of Campinas (Unicamp), Campinas, Sao Paulo, 13084-971, Brazil., Oliveira D; Division of Cardiology, State University of Campinas (Unicamp), Campinas, Sao Paulo, 13084-971, Brazil., Coelho-Filho OR; Division of Cardiology, State University of Campinas (Unicamp), Campinas, Sao Paulo, 13084-971, Brazil., Coelho OR; Division of Cardiology, State University of Campinas (Unicamp), Campinas, Sao Paulo, 13084-971, Brazil., Matos-Souza JR; Division of Cardiology, State University of Campinas (Unicamp), Campinas, Sao Paulo, 13084-971, Brazil., Moura FA; Division of Cardiology, State University of Campinas (Unicamp), Campinas, Sao Paulo, 13084-971, Brazil.; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, USA., de Carvalho LSF; Division of Cardiology, State University of Campinas (Unicamp), Campinas, Sao Paulo, 13084-971, Brazil., Nadruz W; Division of Cardiology, State University of Campinas (Unicamp), Campinas, Sao Paulo, 13084-971, Brazil., Quinaglia T; Division of Cardiology, State University of Campinas (Unicamp), Campinas, Sao Paulo, 13084-971, Brazil., Kimura-Medorima ST; Division of Cardiology, State University of Campinas (Unicamp), Campinas, Sao Paulo, 13084-971, Brazil.
مؤلفون مشاركون: EXCEED-BHS3 Group
المصدر: Cardiovascular diabetology [Cardiovasc Diabetol] 2022 Aug 06; Vol. 21 (1), pp. 147. Date of Electronic Publication: 2022 Aug 06.
نوع المنشور: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840 (Electronic) Linking ISSN: 14752840 NLM ISO Abbreviation: Cardiovasc Diabetol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2002-
مواضيع طبية MeSH: Cardiovascular Diseases* , Diabetes Mellitus, Type 2*/diagnosis , Diabetes Mellitus, Type 2*/drug therapy, Antibodies, Monoclonal, Humanized ; Benzhydryl Compounds ; Female ; Glucosides ; Humans ; Isoprostanes ; Male ; Middle Aged ; PCSK9 Inhibitors ; Proprotein Convertase 9/metabolism ; Treatment Outcome
مستخلص: Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve endothelial dysfunction and reduce cardiovascular events in individuals with type 2 diabetes (T2D). Proprotein convertase subtilisin/kexin 9 (PCSK9i) inhibitors reduce cardiovascular events in high-risk patients. Whether the addition of PCSK9i to SGLT2i treatment adds benefits is not known.
Objectives: To assess the PCSK9-i effect on the endothelial function of T2D individuals under treatment with SGLT2-i.
Methods: Individuals with T2D were randomized in a 1:1 ratio to a 16-week treatment with either empagliflozin (E) or empagliflozin plus evolocumab (EE). The primary endpoint was post-treatment change from baseline in flow-mediated dilation (FMD) at 1-min. Secondary outcomes included changes in plasma levels of nitric oxide metabolites and isoprostane.
Results: A total of 110 patients were enrolled, the mean age was 58 years, and 71% were men. The median post-treatment change in FMD at 1-min was 2.7% (interquartile range [IQR]: 0.9%) and 0.4% (IQR: 0.9%) in the EE and E groups, respectively (p < 0.001). There was a greater increase in plasma levels of nitrate [5.9 (16.5) vs. 2.6 (11.8); p = 0.001] and nitrite [0.14 (0.72) vs. 0.02 (0.74); p = 0.025] in the EE group than in the E group, respectively. Isoprostane reduction was more pronounced in the EE group when compared to the E group [-1.7 (5.9) vs. -1.1 (5.3); p < 0.001).
Conclusions: In individuals with T2D, the addition of evolocumab on top of empagliflozin improves endothelial function.
(© 2022. The Author(s).)
References: Cardiovasc Diabetol. 2021 Apr 24;20(1):89. (PMID: 33894772)
Eur Heart J Cardiovasc Pharmacother. 2019 Oct 1;5(4):237-245. (PMID: 31236571)
Cardiovasc Diabetol. 2021 Mar 26;20(1):74. (PMID: 33771149)
Diabetes Obes Metab. 2018 Jun;20(6):1479-1489. (PMID: 29436756)
Ther Adv Chronic Dis. 2020 Sep 28;11:2040622320959248. (PMID: 33062236)
J Am Coll Cardiol. 2010 Mar 9;55(10):1002-6. (PMID: 20202516)
Circ J. 2012;76(8):2023-30. (PMID: 22640986)
Circulation. 2009 Aug 11;120(6):502-9. (PMID: 19635967)
Cardiovasc Diabetol. 2021 Apr 30;20(1):94. (PMID: 33941192)
J Clin Lipidol. 2012 Jan-Feb;6(1):42-9. (PMID: 22264573)
Circulation. 2012 Aug 7;126(6):753-67. (PMID: 22869857)
J Clin Lipidol. 2018 May - Jun;12(3):669-673. (PMID: 29544724)
Am J Transl Res. 2016 Feb 15;8(2):765-77. (PMID: 27158368)
J Am Heart Assoc. 2020 Jul 21;9(14):e016263. (PMID: 32674634)
Eur Heart J. 2019 Aug 7;40(30):2534-2547. (PMID: 31211361)
Int J Cardiol. 2012 Jul 26;158(3):376-9. (PMID: 21349594)
JAMA. 2018 Apr 17;319(15):1580-1591. (PMID: 29677303)
Arthritis Res Ther. 2015 Oct 08;17:279. (PMID: 26445924)
Hypertension. 2019 Jul;74(1):208-215. (PMID: 31055952)
Lancet Diabetes Endocrinol. 2017 Dec;5(12):941-950. (PMID: 28927706)
J Diabetes Res. 2018 Dec 04;2018:1232583. (PMID: 30622967)
Endocr J. 2011;58(3):171-5. (PMID: 21304215)
Arq Bras Cardiol. 2021 Mar;116(3):516-658. (PMID: 33909761)
Am J Med. 1999 Nov;107(5):479-87. (PMID: 10569303)
Nat Rev Drug Discov. 2021 Aug;20(8):589-610. (PMID: 33976384)
Atherosclerosis. 2011 Jan;214(1):148-50. (PMID: 21115179)
Eur J Clin Invest. 2021 Apr;51(4):e13459. (PMID: 33236356)
Atherosclerosis. 2015 Feb;238(2):159-64. (PMID: 25525743)
Neurologia (Engl Ed). 2022 Mar;37(2):136-150. (PMID: 34906541)
J Diabetes. 2017 May;9(5):434-449. (PMID: 28044409)
Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. (PMID: 31272931)
Circulation. 2007 Mar 13;115(10):1285-95. (PMID: 17353456)
Arterioscler Thromb Vasc Biol. 2011 May;31(5):1240-6. (PMID: 21372302)
Atherosclerosis. 2013 Mar;227(1):118-24. (PMID: 23261174)
Nutr Metab Cardiovasc Dis. 2020 Jun 9;30(6):996-1004. (PMID: 32402582)
Br J Clin Pharmacol. 2016 Jun;81(6):1175-90. (PMID: 26861255)
فهرسة مساهمة: Keywords: Endothelial dysfunction; Flow-mediated dilation; PCSK9i
المشرفين على المادة: 0 (Antibodies, Monoclonal, Humanized)
0 (Benzhydryl Compounds)
0 (Glucosides)
0 (Isoprostanes)
0 (PCSK9 Inhibitors)
EC 3.4.21.- (PCSK9 protein, human)
EC 3.4.21.- (Proprotein Convertase 9)
HDC1R2M35U (empagliflozin)
LKC0U3A8NJ (evolocumab)
تواريخ الأحداث: Date Created: 20220806 Date Completed: 20220809 Latest Revision: 20220827
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC9356512
DOI: 10.1186/s12933-022-01584-8
PMID: 35933413
قاعدة البيانات: MEDLINE
الوصف
تدمد:1475-2840
DOI:10.1186/s12933-022-01584-8